GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Cash Payments

Algernon Pharmaceuticals (XCNQ:AGN) Cash Payments


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.


Algernon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
Executives
Christopher Moreau Director, Senior Officer
Christopher Scott Bryan Senior Officer
James Kinley Senior Officer
Harry J.f. Bloomfield Director
Rajpaul Attariwala Director
Mark Williams Director
Howard Gutman Director
Michael Sadhra Senior Officer
Kulwant Malhi 10% Security Holder